DURHAM, N.C., MARCH 2, 2018 — You know that well-worn advice about picking investments: that past performance doesn’t guarantee future results. The same can be said of selecting clinical trial sites, as Premier Research’s top analgesia expert will explore at the American Pain Society’s 2018 Scientific Summit on March 6 in Anaheim.
Michael Kuss, Vice President for Analgesia, will discuss site selection and other topics specific to the study of osteoarthritis in a Town Hall Talk at 11:10 am on Tuesday, March 6, in the Solutions Theatre. Mr. Kuss will underscore the importance of getting current feedback on site performance before committing, and at why you should look for sites adept at minimizing the placebo effect, a growing problem in pain trials.
Hundreds of sites have the credentials to conduct OA studies — at least on paper. To discern which are best able to deliver the clean, conclusive data that leads to commercial success, plan to attend this informative presentation at APS 2018.
About Premier Research
Premier Research is a leading clinical development service provider that helps highly innovative biotech, specialty pharma, and medical device companies transform breakthrough ideas into reality. The company has a wealth of experience in the execution of global, regional and local clinical development programs with a special focus on addressing unmet needs in areas such as analgesia, dermatology, medical device, neuroscience, oncology, pediatrics, and rare disease. Premier Research operates in 84 countries and employs 1,100 professionals, including a strong international network of clinical monitors and project managers, regulatory, data management, statistical, scientific, and medical experts. They are focused on smart study design for advanced medicines that allow life-changing treatments.